2 results
Not approvedWill not start
To induce a vaccine specific immune response, hereby we hope to introduce the possibility of a new treatment to improve patient outcome and survival.
Approved WMORecruiting
The primary objective is to prospectively assess whether a sequential approach with an induction period of 12 weeks with encorafenib + binimetinib followed by an immunotherapy combination with nivolumab + ipilimumab improves Progression Free…